Company profile for Context Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context’s lead program is Apristor (Onapristone XR), an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) metastatic breast and ovarian cancers. In addition, Context is advancing CTX-030916, a potential best-in-class oral antiprogestin for the ...
Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context’s lead program is Apristor (Onapristone XR), an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) metastatic breast and ovarian cancers. In addition, Context is advancing CTX-030916, a potential best-in-class oral antiprogestin for the treatment of uterine fibroids and endometriosis, and a discovery-stage program targeting Sigma1

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
3675 Market Street, Suite 200 Philadelphia, PA 19104
Telephone
Telephone
267.225.7416
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/07/3183563/0/en/Context-Therapeutics-Highlights-CT-95-and-CT-202-Programs-at-2025-SITC-Annual-Meeting.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3182001/0/en/Context-Therapeutics-Reports-Third-Quarter-2025-Operating-and-Financial-Results.html

GLOBENEWSWIRE
05 Nov 2025

https://www.globenewswire.com/news-release/2025/10/28/3175275/0/en/Context-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html

GLOBENEWSWIRE
28 Oct 2025

https://www.globenewswire.com/news-release/2025/10/06/3161628/0/en/Context-Therapeutics-Announces-Poster-Presentations-at-the-Society-for-Immunotherapy-of-Cancer-s-SITC-40th-Annual-Meeting.html

GLOBENEWSWIRE
06 Oct 2025

https://www.globenewswire.com/news-release/2025/10/03/3161213/0/en/Context-Therapeutics-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
03 Oct 2025

https://www.globenewswire.com/news-release/2025/08/27/3139899/0/en/Context-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html

GLOBENEWSWIRE
27 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty